Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

December 2, 2022 2:54 pm Published by redakteur

Ho JNHG, Schmidt D, Lowinus T, […] Zeiser R: Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood 140(10), 1167-1181, doi: 10.1182/blood.2022016082 (2022).

Categorised in:

This post was written by redakteur

Get in contact

Coordinator
Tanja Wilde, M.A.
Medical Center – University of Freiburg

Louise Grant(Manager NeuroMac School)

+49 (0)761 / 270-51190 tanja.wilde@uniklinik-freiburg.de

Louise.Grant@mri.tum.de